The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty-eight databases from inception to April 2015. STUDY SELECTION: Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiety disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome. DATA EXTRACTION AND SYNTHESIS: Study quality was assessed using the Cochrane risk of bias tool. All review stages were conducted independently by 2 reviewers. Where possible, data were pooled using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Patient-relevant/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and AEs. RESULTS: A total of 79 trials (6462 participants) were included; 4 were judged at low risk of bias. Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials. Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; 3 trials), reduction in pain (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment (on a 0-10-point scale; weighted mean difference [WMD], -0.46 [95% CI, -0.80 to -0.11]; 6 trials), and average reduction in the Ashworth spasticity scale (WMD, -0.36 [95% CI, -0.69 to -0.05]; 7 trials). There was an increased risk of short-term AEs with cannabinoids, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. CONCLUSIONS AND RELEVANCE: There was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mild to moderate central nervous or gastro-intestinal side effects are more common with cannabinoids than with placebo but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medical uses of THC-based cannabinoids are associated with an increased risk of short-term adverse effects, but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous systematic reviews have been limited in their coverage of all relevant diseases, but most importantly primarily ignored the fact that medical cannabinoid products—a term that encompasses all plant-derived and synthetic derivatives—differ in their pharmacology [1–5].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, data analysis using SMD allowed the inclusion of a large variety of measurements in the evaluation of the outcomes and allowed us to include many more RCTs for all relevant medical indications than in a previous extensive meta-analysis [3].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that efforts to selfmanage depression with cannabis are increasing [71][72][73][74][75] (also Aaron L. Sarvet, MPH, written communication, January 2, 2018) despite lack of evidence that cannabinoids are effective for this purpose 76,77 ; prospectively, cannabis worsens the course of depressive disorders.78”
From Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States (2018) · cites this paper as [75]
In the citing paper
“Several clinical studies have demonstrated the analgesic effects of cannabinoids in human disease states, including pain associated with diabetes, chemotherapy, multiple sclerosis, and fibromyalgia (Lynch and Ware, 2015;Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“A comprehensive meta-analysis shows that medicinal cannabis and cannabinoids effectively alleviate different types of pain, such as neuropathic, fibromyalgia, multiple sclerosis, cancer, diabetic neuropathy, refractory pain due to multiple sclerosis or other neurological conditions, rheumatoid arthritis, noncancer pain, central pain, musculoskeletal problems, and chemotherapy-induced pain (Whiting”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“Although several studies show that 'medical cannabis' can improve various types of pain, cannabimimetic side effects, which include drowsiness or fatigue, dizziness, dry mouth, nausea, and cognitive effects, have also been reported (Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Cochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity
Bohannon, R. W., & Smith, M. B. (1987) · Physical Therapy · doi:10.1093/ptj/67.2.206 · Cited by 5,461
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Flagged first, then by citations
Research works printed but not linked: 20
- [8]8. Canadian Agency for Drugs and Technologies in Health. CADTH Peer Review Checklist for Search Strategies (Internet). Ottawa, Canada: CADTH; 2013. https://www.cadth.ca/resources/finding-evidence /cadth-peer-review-checklist-search-strategies. Accessed March 17, 2014.
- [14]14. Broder LE, Lean NL, Hilsenbeck SG. A randomized blinded clinical trial comparing delta-9-tetrahydrocannabinol (THC) and hydroxizine (HZ) as antiemetics (AE) for cancer chemotherapy (CT). Proc Am Assoc Cancer Res. 1982;23:514.
- [16]16. Hagenbach U, Luz S, Brenneisen R, Mäder M. The treatment of spasticity with D9-tetrahydrocannabinol (D9-THC) in patients with spinal cord injury. Paper presented at: IACM 2nd Conference on Cannabinoids in Medicine; September 12-13, 2003; Cologne, Germany.
- [18]18. Denver, CO. Am J Respir Crit Care Med. 2011;183(1):A2720.
- [46]46. Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer. 1982;50 (4):636-645.
- [48]48. Harden-Harrison MM, Munsell MF, Fisch MJ, et al. Dronabinol for the prevention of nausea from cyclophosphamide and/or adriamycin. Paper presented at: International MASCC/ISOO Symposium: Supportive Care in Cancer; June 28-30, 2012; New York, NY. Support Care Cancer. 2012;20:S209-S210.
- [50]50. Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol. 1989;8:326.
- [52]52. Chan HS, MacLeod SM, Correia JA. Nabilone vs prochlorperazine for control of cancer chemotherapy-induced emesis in children. Proc Am Soc Clin Oncol. 1984;3:108.
- [54]54. Frytak S, Moertel CG, Ofallon JR. Comparison of delta-9-tetrahydrocannabinol (THC), prochlorperazine (PCP) and placebo as anti-emetics for cancer-chemotherapy. Proc Am Assoc Cancer Res. 1979;20:391.
- [56]56. McCabe M, Smith FP, Goldberg D, et al. Comparative trial of oral 9 tetrahydrocannabinol and prochlorperazine for cancer chemotherapy related nausea and vomiting. Proc Am Assoc Cancer Res and Am Soc Clin Oncol. 1981;22:416.
- [63]63. Ware M, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Paper presented at: Canadian Rheumatology Association Meeting; February 18-21, 2009; Kananaskis, AB: Canada. Abstract 149 J Rheumatol. 2009;36(11):2607.
- [80]80. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
- [90]90. Abrams DI, Jay CA, Vizoso H, et al. Smoked cannabis therapy for HIV-related painful peripheral neuropathy: results of a randomized, placebo-controlled clinical trial. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands.
- [116]116. Cambridge Laboratories Ltd. A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain. metaRegister of Controlled Trials. http://isrctn.org /ISRCTN15330757. Accessed April 7, 2014.
- [136]136. Zajicek J, Reif M, Schnelle M; UK MUSEC Study Investigators. Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis -results of the MUSEC study. Paper presented at: IACM 5th Conference on Cannabinoids in Medicine; October 2-3, 2009; Cologne, Germany. 137.
- [93]93. Collin C, Ambler Z, Kent R, McCalla R. A randomised controlled study of Sativex® in patients with symptoms of spasticity due to multiple sclerosis. Paper presented at: 22nd Congress of the ECTRIMS; September 27-30, 2006; Madrid, Spain. 138. Robson P, Wade D, Makela P, House H, Bateman C. Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands. 139. Center for Medicinal Cannabis Research. Short-term effects of medicinal cannabis therapy on spasticity in multiple sclerosis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00248378. Accessed April 7, 2014. 140. Institut fur Klinische Forschung Germany;
- [155]155. Rohleder C, Pahlisch F, Schaefer C, et al. The endocannabinoid system as a pharmacological target for antipsychotic treatment and more? Paper presented at: 8th International Conference on Early Psychosis: From Neurobiology to Public Policy; October 11-13, 2012; San Francisco, CA. Early Interv Psychiatry. 2012;6(suppl 1):7 doi:10.1111/j.1751-7893 .2012.00392.x. · DOI
- [164]164. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. MeDRA (Medical Dictionary for Regulatory Activities). http://www .meddra.org/. Accessed September 2, 2014.
- [178]178. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids as Co-Analgesics: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health;2010.
- [179]179. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids for the Management of Neuropathic Pain: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health);2010.
Cited by
Sorted by citations
Items 501–600 of 1,002
Effects of Legal Access to Cannabis on Scheduled II–V Drug Prescriptions
Stith, S. S., Vigil, J. M., Adams, I. M., & Reeve, A. P. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.07.017 · Cited by 37
Therapeutic use of cannabis: Prevalence and characteristics among adults in Ontario, Canada
Hamilton, H. A., Brands, B., Ialomiteanu, A., & Mann, R. E. (2017) · Canadian Journal of Public Health · doi:10.17269/cjph.108.6130 · Cited by 37
Vigil, J. M., Stith, S. S., Diviant, J. P., Brockelman, F., Keeling, K., & Hall, B. (2018) · Medicines · doi:10.3390/medicines5030075 · Cited by 39
The Intricate Influence of the Placebo Effect on Medical Cannabis and Cannabinoids
Gertsch, J. (2018) · Medical Cannabis and Cannabinoids · doi:10.1159/000489291 · Cited by 37
Masocha, W. (2018) · Pain Research and Management · doi:10.1155/2018/5234943 · Cited by 37
Sharon, H., Goldway, N., Goor‐Aryeh, I., Eisenberg, E., & Brill, S. (2018) · Journal of Pain Research · doi:10.2147/jpr.s159852 · Cited by 37
Medical Cannabis: Effects on Opioid and Benzodiazepine Requirements for Pain Control
O’Connell, M., Sandgren, M., Frantzen, L., Bower, E., & Erickson, B. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019854221 · Cited by 38
Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence
Babalonis, S. L., & WALSH, S. L. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.03.002 · Cited by 39
Synthetic biology for natural product drug production and engineering
Romanowski, S. B., & Eustáquio, A. S. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.09.006 · Cited by 37
Deidda, R., Dispas, A., Bleye, C. D., Hubert, P., & Ziémons, E. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.339184 · Cited by 37
Abd‐Nikfarjam, B., Dolati‐Somarin, A., Rahimi, V. B., & Askari, V. R. (2023) · BioFactors · doi:10.1002/biof.1936 · Cited by 37
Use of Cannabinoids for Spasticity and Pain Management in MS
Chohan, H., Greenfield, A. L., Yadav, V., & Graves, J. S. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0385-y · Cited by 36
Medical cannabis: aligning use to evidence‐based medicine approach
Schleider, L. B., Abuhasira, R., & Novack, V. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13657 · Cited by 37
Mlost, J., Wąsik, A., & Starowicz, K. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.029 · Cited by 38
Karoly, H. C., Mueller, R. L., Bidwell, L. C., & Hutchison, K. E. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14256 · Cited by 37
Medical cannabis as an alternative therapeutics for Parkinsons’ disease: Systematic review
Bougea, A. M., Koros, C., Simitsi, A., Chrysovitsanou, C., Leonardos, A., & Stefanis, L. (2020) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2020.101154 · Cited by 36
Bruce, D., Grove, T. J., Foster, E., & Shattell, M. M. (2020) · Journal of Women s Health · doi:10.1089/jwh.2020.8437 · Cited by 36
Lim, X. Y., Tan, T. Y. C., Rosli, S. H. M., Sa’at, M. N. F., Ali, S. S., & Mohamed, A. F. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245471 · Cited by 38
Amaral, C., Trouille, F. M., Almeida, C. F., Correia‐da‐Silva, G., & Teixeira, N. A. A. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.105876 · Cited by 36
Nigro, E., Formato, M., Crescente, G., & Daniele, A. (2021) · Molecules · doi:10.3390/molecules26092668 · Cited by 54
Wagoner, K. G., Lazard, A. J., Romero-Sandoval, E. A., & Reboussin, B. A. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0166 · Cited by 39
The Impact of Early Life Exposure to Cannabis: The Role of the Endocannabinoid System
Martínez-Peña, A. A., Perono, G. A., Gritis, S. A., Sharma, R., Selvakumar, S., Walker, O. S., Gurm, H., Holloway, A. C., & Raha, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168576 · Cited by 39
Illicit Substance Use in US Adults With Chronic Low Back Pain
Shmagel, A., Krebs, E. E., Ensrud, K. E., & Foley, R. N. (2016) · Spine · doi:10.1097/brs.0000000000001702 · Cited by 36
Religious Involvement and Marijuana Use for Medical and Recreational Purposes
Burdette, A. M., Webb, N. S., Hill, T. D., Haynes, S. H., & Ford, J. A. (2018) · Journal of Drug Issues · doi:10.1177/0022042618770393 · Cited by 36
Hansen, J. S., Gustavsen, S., Roshanisefat, H., Kant, M., Biering‐Sørensen, F., Andersen, C. Y., Olsson, A., Chow, H. H., Asgari, N., Hansen, J. R., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16081079 · Cited by 40
Isahq, M. S., Afridi, M. S., Ali, J., Hussain, M. M., Ahmad, S., & Kanwal, F. (2015) · Asian Pacific Journal of Tropical Disease · doi:10.1016/s2222-1808(15)60953-7 · Cited by 35
Schreck, B., Wagneur, N., Caillet, P., Gérardin, M., Cholet, J., Spadari, M., Authier, N., Tournebize, J., Gaillard, M., Serre, A., et al. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.09.038 · Cited by 35
Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice
Nealon, C. M., Henderson, A. N., Hale, D. E., & Morgan, D. J. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.026 · Cited by 34
Cannabis Use and Low-Back Pain: A Systematic Review
First, L., Douglas, W., Habibi, B., Singh, J. R., & Sein, M. T. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0077 · Cited by 37
The Efficacy of Medical Marijuana in the Treatment of Cancer-Related Pain
Pawasarat, I. M., Schultz, E. M., Frisby, J. C., Mehta, S. D., Angelo, M., Hardy, S., & Kim, T. W. B. (2020) · Journal of Palliative Medicine · doi:10.1089/jpm.2019.0374 · Cited by 35
Hordowicz, M., Klimkiewicz, A., Jarosz, J., Wysocka, M., & Jastrzębska, M. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108652 · Cited by 35
Cannabis and orofacial pain: a systematic review
Grossman, S., Tan, H., & Gadiwalla, Y. (2021) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2021.06.005 · Cited by 39
The Therapeutic Potential of Cannabis in Counteracting Oxidative Stress and Inflammation
Graczyk, M., Lewandowska, A. A., & Dzierżanowski, T. (2021) · Molecules · doi:10.3390/molecules26154551 · Cited by 36
Developmental disabilities across the world: A scientometric review from 1936 to 2020
Carollo, A., Bonassi, A., Lim, M., Gabrieli, G., Setoh, P., Dimitriou, D., Aryadoust, V., & Esposito, G. (2021) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2021.104031 · Cited by 35
A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome
Abi‐Jaoude, E., Bhikram, T., Parveen, F., Levenbach, J., Lafrenière‐Roula, M., & Sandor, P. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0091 · Cited by 35
Cannabis use among adults undergoing cancer treatment
Azizoddin, D. R., Cohn, A. M., Ulahannan, S. V., Henson, C. E., Alexander, A. C., Moore, K. N., Holman, L. L., Boozary, L. K., Sifat, M., & Kendzor, D. E. (2023) · Cancer · doi:10.1002/cncr.34922 · Cited by 34
Cannabinoids and the Gastrointestinal Tract
Camilleri, M., & Zheng, T. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.07.031 · Cited by 35
Gertsch, J. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13676 · Cited by 35
History of Marijuana Use Does Not Affect Outcomes on the Liver Transplant Waitlist
Kotwani, P., Saxena, V., Dodge, J. L., Roberts, J. P., Yao, F. Y., & Hameed, B. (2018) · Transplantation · doi:10.1097/tp.0000000000002045 · Cited by 34
Possible therapeutic applications of cannabis in the neuropsychopharmacology field
Fernández‐Ruíz, J., Galve‐Roperh, I., Sagredo, O., & Guzmán, M. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.01.013 · Cited by 35
Cannabinoids and the Coronavirus
Hill, K. P. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0035 · Cited by 34
Shah, S., Gupta, A. S., & Kumar, P. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_488_18 · Cited by 34
The Effect of Anti-seizure Medications on the Propagation of Epileptic Activity: A Review
Khateb, M., Bosak, N., & Herskovitz, M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.674182 · Cited by 35
Zhao, H., Xiong, H., & Chen, J. (2021) · Sustainability · doi:10.3390/su13116419 · Cited by 34
The Effects of Cannabinoids on Sleep
Kolla, B. P., Hayes, L., Cox, C., Eatwell, L., Deyo-Svendsen, M. E., & Mansukhani, M. P. (2022) · Journal of Primary Care & Community Health · doi:10.1177/21501319221081277 · Cited by 38
Moon, A. S., LeRoy, T. E., Yacoubian, V., Gedman, M., Aidlen, J. P., & Rogerson, A. L. (2022) · Global Spine Journal · doi:10.1177/21925682221099857 · Cited by 34
Current situation and progress of drugs for reducing intraocular pressure
Liu, P., Wang, F., Song, Y., Wang, M., & Zhang, X. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221140392 · Cited by 38
The relationship between cannabis and cardiovascular disease: clearing the haze
Chandy, M., Jiménez-Téllez, N., & Wu, J. C. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01121-6 · Cited by 38
Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review
Bouquié, R., Deslandes, G., Mazaré, H., Cogné, M., Mahé, J., Grégoire, M., & Jolliet, P. (2018) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12373 · Cited by 34
Lack of Communication about Medical Marijuana Use between Doctors and Their Patients
Kondrad, E. C., Reed, A. J., Simpson, M., & Nease, D. E. (2018) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2018.05.170462 · Cited by 33
Campbell, G., Hall, W., & Nielsen, S. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1509842 · Cited by 33
Medical cannabis and cannabinoids in rheumatology: where are we now?
Sarzi‐Puttini, P., Batticciotto, A., Atzeni, F., Bazzichi, L. M., Franco, M. D., Salaffi, F., Marotto, D., Ceribelli, A., Ablin, J. N., & Häuser, W. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1665997 · Cited by 34
Ferber, S. G., Trezza, V., & Weller, A. (2019) · Developmental Psychobiology · doi:10.1002/dev.21944 · Cited by 38
Ponton, J. A., Smyth, K. A., Soumbasis, E., Llanos, S. A., Lewis, M. H., Meerholz, W. A., & Tanguay, R. L. (2020) · Journal of Medical Case Reports · doi:10.1186/s13256-020-02478-7 · Cited by 39
Velayudhan, L., McGoohan, K. L., & Bhattacharyya, S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.35913 · Cited by 33
Matson, T. E., Carrell, D., Bobb, J. F., Cronkite, D., Oliver, M. M., Luce, C., Ghitza, U. E., Hsu, C. W., Campbell, C. I., Browne, K. C., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.9375 · Cited by 33
Slawek, D. E. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00563-0 · Cited by 33
Duffy, S., de Kock, S., Misso, K., Noake, C., Ross, J., & Stirk, L. (2016) · Journal of the Medical Library Association JMLA · doi:10.3163/1536-5050.104.4.011 · Cited by 33
Self-citationUse and caregiver-reported efficacy of medical cannabis in children and adolescents in Switzerland
Zürcher, K., Dupont, C., Weber, P., Grunt, S., Wilhelm, I., Eigenmann, D. E., Reichmuth, M. L., Fankhauser, M., Egger, M., & Fenner, L. (2021) · European Journal of Pediatrics · doi:10.1007/s00431-021-04202-z · Cited by 34
Wissel, J., & Ri, S. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.2021072 · Cited by 32
Medical cannabis: From research breakthroughs to shifting public perceptions and ensuring safe use
Hossain, M. K., & Chae, H. (2024) · Integrative Medicine Research · doi:10.1016/j.imr.2024.101094 · Cited by 32
Fu, X., Wang, Y., Wang, C., Wu, H., Li, J., Li, M., Ma, Q., & Yang, W. (2018) · Clinical Rehabilitation · doi:10.1177/0269215517745348 · Cited by 32
Becker, W., Alrafas, H. R., Wilson, K. M., Miranda, K., Culpepper, C. D., Chatzistamou, I., Cai, G., Nagarkatti, M., & Nagarkatti, P. S. (2020) · iScience · doi:10.1016/j.isci.2020.101504 · Cited by 35
Consumers' perceptions of hemp products for animals.
Kogan, L. R., Hellyer, P. W., & Robinson, N. G. (2016) · Journal of the American Holistic Veterinary Medical Association · Cited by 32
Cannabis use among military veterans: A great deal to gain or lose?
Turna, J., & MacKillop, J. M. (2021) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.101958 · Cited by 36
Cannabis Use in Older Adults: A Perspective
Solomon, H. V., Greenstein, A. P., & DeLisi, L. E. (2021) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000289 · Cited by 35
Adams, P. J., Rychert, M., & Wilkins, C. (2021) · Addiction · doi:10.1111/add.15483 · Cited by 32
Patzke, C., Dai, J., Brockmann, M. M., Sun, Z., Fenske, P., Rosenmund, C., & Südhof, T. C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01095-0 · Cited by 33
Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia
Boehnke, K. F., Gagnier, J. J., Matallana, L. K., & Williams, D. A. (2021) · Journal of Pain · doi:10.1016/j.jpain.2021.06.007 · Cited by 32
Reimer, C., Kufs, J. E., Rautschek, J., Regestein, L., Valiante, V., & Hillmann, F. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01143-8 · Cited by 32
Cannabinoid hyperemesis syndrome
Ruffle, J. K., Bajgoric, S., Samra, K., Chandrapalan, S., Aziz, Q., & Farmer, A. D. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000489 · Cited by 32
Drug Vaping: From the Dangers of Misuse to New Therapeutic Devices
Varlet, V. (2016) · Toxics · doi:10.3390/toxics4040029 · Cited by 32
Hakkarainen, P., Decorte, T., Sznitman, S. R., Karjalainen, K., Barratt, M. J., Frank, V. A., Lenton, S. R., Potter, G., Werse, B., & Wilkins, C. (2017) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2017.1411888 · Cited by 32
Abdelaal, M., Mosher, P. J., Gupta, A., Hannon, B., Cameron, C., Berman, M., Moineddin, R., Avery, J., Mitchell, L., Li, M., et al. (2021) · Cancers · doi:10.3390/cancers13040770 · Cited by 31
Francisco, G. E., Wissel, J., Platz, T., & Li, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-58505-1_9 · Cited by 31
Cannabis Use, Medication Management and Adherence Among Persons Living with HIV
Vidot, D. C., Lerner, B., & González, R. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1782-x · Cited by 30
Wilson, M., Gogulski, H. Y., Cuttler, C., Bigand, T. L., Oluwoye, O. A., Barbosa‐Leiker, C., & Roberts, M. A. (2017) · Addictive Behaviors · doi:10.1016/j.addbeh.2017.10.012 · Cited by 32
Priority Considerations for Medicinal Cannabis-Related Research
Bonn‐Miller, M. O., Pollack, C. V., Casarett, D., Dart, R. C., ElSohly, M. A., Good, L. I., Guzmán, M., Hanuš, L., Hill, K. P., Huestis, M. A., et al. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0045 · Cited by 32
Lorenzini, K. I., & Girardin, F. R. (2019) · Liver International · doi:10.1111/liv.14283 · Cited by 31
Yang, X., Bam, M., Nagarkatti, P. S., & Nagarkatti, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-52362-8 · Cited by 33
Medical marijuana and workers' compensation claiming
Ghimire, K., & Maclean, J. C. (2020) · Health Economics · doi:10.1002/hec.3992 · Cited by 32
Prevalence and Correlates of Medicinal Cannabis Use Among Adolescents
Wardell, J. D., Rueda, S., Elton‐Marshall, T., Mann, R. E., & Hamilton, H. A. (2020) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2020.07.032 · Cited by 31
Schneider, T., Zurbriggen, L., Dieterle, M., Mauermann, E., Frei, P., Mercer‐Chalmers‐Bender, K., & Ruppen, W. (2021) · Pain · doi:10.1097/j.pain.0000000000002310 · Cited by 32
Pugazhendhi, A., Suganthy, N., Chau, T. P., Sharma, A. K., Unpaprom, Y., Ramaraj, R., Karuppusamy, I., & Brindhadevi, K. (2021) · Process Biochemistry · doi:10.1016/j.procbio.2021.08.025 · Cited by 32
Tateo, S. (2016) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12422 · Cited by 32
Adverse Impact of Cannabis on Human Health
Chandy, M., Nishiga, M., Wei, T.-T., Hamburg, N. M., Nadeau, K. C., & Wu, J. C. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-052422-020627 · Cited by 33
Building smart cannabis policy from the science up
Weiss, S. R. B., Howlett, K. D., & Baler, R. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.01.007 · Cited by 35
Medical marijuana in pediatric oncology: A review of the evidence and implications for practice
Ananth, P. J., Reed-Weston, A. E., & Wolfe, J. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26826 · Cited by 31
Cannabinoids and cancer pain: A new hope or a false dawn?
Brown, M. R. D., & Farquhar-Smith, W. P. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.020 · Cited by 33
Cannabinoid Use in Patients With Gastroparesis and Related Disorders: Prevalence and Benefit
Jehangir, A., & Parkman, H. P. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000181 · Cited by 30
Meinhofer, A., Witman, A. E., Murphy, S. M., & Bao, Y. (2019) · Addiction · doi:10.1111/add.14661 · Cited by 33
Crescioli, G., Lombardi, N., Bettiol, A., Menniti‐Ippolito, F., Cas, R. D., Parrilli, M., Lungo, M. D., Gallo, E. R., Mugelli, A., Maggini, V., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14140 · Cited by 30
Cannabis and work: Need for more research
Howard, J., & Osborne, J. C. (2020) · American Journal of Industrial Medicine · doi:10.1002/ajim.23170 · Cited by 29
Babiloni, A. H., Beetz, G., Bruneau, A., Martel, M. O., Cistulli, P. A., Nixdorf, D. R., Conway, J. M., & Lavigne, G. J. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2021.101459 · Cited by 30
Wen, J., Wen, H., Butler, J. S., & Talbert, J. (2021) · Health Economics · doi:10.1002/hec.4237 · Cited by 30
Cannabis and Inflammation in HIV: A Review of Human and Animal Studies
Ellis, R. J., Wilson, N., & Peterson, S. N. (2021) · Viruses · doi:10.3390/v13081521 · Cited by 33
Lester, K. J., Coleman, J. R. I., Roberts, S., Keers, R., Breen, G. D., Bögels, S. M., Creswell, C., Hudson, J. L., McKinnon, A., Nauta, M. H., et al. (2016) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32467 · Cited by 31
Korn, L., Haynie, D. L., Luk, J. W., & Simons‐Morton, B. G. (2018) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2018.05.003 · Cited by 34
Monitoring Perinatal Exposure to Cannabis and Synthetic Cannabinoids
Carlier, J., Huestis, M. A., Zaami, S., Pichini, S., & Busardò, F. P. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000667 · Cited by 30
Herbst, J., & Musgrave, G. (2019) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.09.023 · Cited by 31
Metadata
- Authors
- Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., & Kleijnen, J.
- Affiliations
- University Hospitals Bristol NHS Foundation Trust (GB)
- Kleijnen Systematic Reviews (United Kingdom) (GB)
- Department of Medical, Oral, and Biotechnological Sciences, University “G. D'Annunzio” of Chieti-Pescara, Chieti, Italy5Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
- Medical School, Universidad Peruana de Ciencias Aplicadas (UPC), Lima, Peru7Health Outcomes and Clinical Epidemiology Section, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
- Radboud University Medical Center (NL)
- Institut für Epidemiologie und kongenitale Erkrankungen, Cepicon GmbH, Hamburg, Germany
- Maastricht University (NL)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-06-23
- Volume
- 313
- Issue
- 24
- Pages
- 2456
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2120227293
- Semantic Scholar
- 029bce497e0633eb2a7895cfd3b315f9c462dd5f
- Cited by
- 2,169
- References
- 137
- Citations by year
- 2026: 119 · 2025: 166 · 2024: 168 · 2023: 200 · 2022: 220 · 2021: 262 · 2020: 272 · 2019: 230 · 2018: 209 · 2017: 159 · 2016: 131 · 2015: 33
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Bristol Research (University of Bristol) (publishedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Americanae (AECID Library) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Explore Bristol Research (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- cannabinoids, medical cannabis, nausea and vomiting, chemotherapy-induced nausea, chronic pain, spasticity, multiple sclerosis, depression, anxiety, sleep disorders, psychosis, glaucoma, Tourette syndrome, adverse events, quality of life, activities of daily living, risk of bias, placebo comparison
- MeSH terms
- Anorexia, Mental Disorders, Cannabinoids, Tourette Syndrome, Glaucoma, Humans, Muscle Spasticity, Nausea, Randomized Controlled Trials as Topic, Chronic Pain, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
